We’ve recently updated our valuation analysis.

Wai Chun Bio-Technology Valuation

Is 660 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 660?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 660. This is calculated by dividing 660's market cap by their current preferred multiple.
What is 660's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	HK$15.26m

660 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.2x
Enterprise Value/EBITDA	6.1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 660's PS Ratio compare to its peers?

The above table shows the PS ratio for 660 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PS	Estimated Growth	Market Cap
Peer Average	0.3x
1695 S&P International Holding	0.4x	n/a	HK$59.4m
359 China Haisheng Juice Holdings	0.04x	n/a	HK$63.2m
1699 China Putian Food Holding	0.1x	n/a	HK$90.0m
1340 Huisheng International Holdings	0.5x	n/a	HK$38.8m
660 Wai Chun Bio-Technology	0.02x	n/a	HK$15.3m

Price-To-Sales vs Peers: 660 is good value based on its Price-To-Sales Ratio (0x) compared to the peer average (0.3x).

Price to Earnings Ratio vs Industry

How does 660's PE Ratio compare vs other companies in the HK Food Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	16.2%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	16.2%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: 660 is good value based on its Price-To-Sales Ratio (0x) compared to the Hong Kong Food industry average (0.6x)

Price to Sales Ratio vs Fair Ratio

What is 660's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

660 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.02x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 660's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of 660 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 660's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 660's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Take a look at our analysis of 660's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Wai Chun Bio-Technology regulatory filings.
Potentially undervalued companies in the Food, Beverage & Tobacco industry.